3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
7
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Philadelphia Chromosome
2
Leukemia, Myeloid
2
Leukemia
2
Myeloproliferative Disorders
1
Leukemia, Myeloid, Chronic-Phase
1
Bronchiolitis Obliterans Syndrome
1
Interventions
Cytarabine
5
Whole-Body Irradiation
3
Specimen Handling
3
Injections
3
CPX-351
3
Blood Specimen Collection
3
venetoclax
2
luspatercept
2
ivosidenib
2
fludarabine phosphate
2
fludarabine
2
decitabine and cedazuridine drug combination
2
Tacrolimus
2
Peripheral Blood Stem Cell Transplantation
2
Mycophenolic Acid
2
Melphalan
2
Liposomes
2
Idarubicin
2
Granulocyte Colony-Stimulating Factor
2
Gemtuzumab
2
Filgrastim
2
Daunorubicin
2
Cyclosporine
2
Cyclophosphamide
2
Busulfan
2
Biopsy
2
Azacitidine
2
tocilizumab
1
selinexor
1
ruxolitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Myeloproliferative Disorders
×
asciminib
×
30 days
×
Clear all
NCT05456191
2026-05-27
ASC4START
Novartis
Phase 3
Active not recruiting
568 enrolled
11 charts